Candidate biomarker analyses in gastric or gastro-esophageal junction carcinoma: REGARD trial of single-agent ramucirumab (RAM) vs. placebo (PL).

4029 Background: Vascular endothelial growth factors (VEGFs) are key regulators of tumor angiogenesis. RAM, a recombinant human IgG1 monoclonal antibody specific for VEGF receptor 2 (VEGFR2), inhib...